Galectin Therapeutics
GALT, the leading developer of therapeutics that target galectin
proteins to treat fibrosis and cancer, today announced that the U.S. Food and
Drug Administration (FDA) has granted GR-MD-O2
(galactoarabino-rhamnogalacturonate) Fast Track designation for non-alcoholic
steatohepatitis (NASH) with hepatic fibrosis, commonly known as fatty liver
disease with advanced fibrosis.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in